|Bid||26.20 x 100|
|Ask||29.50 x 300|
|Day's Range||27.70 - 28.36|
|52 Week Range||21.35 - 38.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.38|
MENLO PARK, Calif., Nov. 09, 2017-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...
-FDA decision on New Drug Application expected by June 30, 2018. -Licensed exclusive, worldwide rights to lebrikizumab from Roche. -Completed patient enrollment in two Phase 3 trials for the treatment ...
Dermira to transition development and commercialization responsibility for CIMZIA ® in psoriasis back to UCB Decision reflects both companies’ strategic priorities UCB remains committed to bringing CIMZIA ...
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Dermira, Inc. (NASDAQ: DERM ), following which we have published ...